Today: 1 May 2026
Browse Category

NYSE:JNJ 5 February 2026 - 28 April 2026

Dow Jones Today: Why The Dow Is Holding Up While Nasdaq Sinks On AI Worries

Dow Jones Today: Why The Dow Is Holding Up While Nasdaq Sinks On AI Worries

The Dow rose 100.62 points to 49,268.41 on Tuesday, lifted by gains in Coca-Cola and Johnson & Johnson, while the S&P 500 fell 0.64% and the Nasdaq dropped 1.24% as investors sold AI-linked shares. Coca-Cola reported Q1 net revenue up 12% and raised its full-year earnings forecast. Nvidia, AMD, and Arm all declined sharply. Brent crude hovered near $111 amid U.S.-Iran tensions and OPEC uncertainty.
28 April 2026
·······
Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Johnson & Johnson reported first-quarter revenue of $24.1 billion, up 9.9%, and adjusted earnings of $2.70 per share, both above analyst estimates. Sales of cancer drug Darzalex hit $4 billion, while Stelara fell 60% to $656 million. The company raised its 2026 outlook, nudging full-year sales guidance to $100.8 billion. J&J shares slipped 0.27% to $237.96 in early trading.
14 April 2026
···
Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson filed with the European Medicines Agency to expand Tecvayli’s use as a solo treatment for adults with relapsed or refractory multiple myeloma after one prior therapy. The filing follows U.S. approval of Tecvayli with Darzalex last week and is supported by a phase 3 trial showing Tecvayli reduced disease progression or death by 71% versus standard care.
10 March 2026
···
Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next

Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next

Johnson & Johnson shares fell 0.7% to $245.07 Wednesday after its lupus drug nipocalimab received FDA Fast Track status. The stock lagged a broader market rally, with the S&P 500 ETF up nearly 1%. Investors weighed pipeline progress against ongoing legal risks and recent defensive trading. Johnson & Johnson will present at the Barclays Global Healthcare Conference on March 10.
4 March 2026
··
Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx shares surged 78% to $113.92 after Gilead Sciences agreed to acquire the company for $115 per share in cash, plus a $5 contingent payout tied to anito-cel sales, valuing Arcellx at up to $7.8 billion. The companies expect to close the deal in Q2 2026. Trading volume in Arcellx topped 11 million shares by mid-morning. Gilead shares fell 0.5%.
23 February 2026
····
Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson shares closed at $242.49 on Friday, down 1.8%. The company released new three-year Tremfya data in ulcerative colitis over the weekend. J&J stock goes ex-dividend Feb. 24, with a $1.30-per-share payout set for March 10. A potential $20 billion sale of its DePuy Synthes orthopedics unit remains under discussion.
22 February 2026
···
Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson shares fell 1.8% to $242.49 Friday after Reuters reported the company is preparing a potential $20 billion sale of its DePuy Synthes orthopedics unit. J&J released new long-term data for Tremfya in ulcerative colitis, showing 80.8% remission at week 140. The company did not comment on the reported DePuy sale. Investors await management updates in March and April.
21 February 2026
··
Johnson & Johnson stock price slips after hours as healthcare lags — what’s next for JNJ

Johnson & Johnson stock price slips after hours as healthcare lags — what’s next for JNJ

Johnson & Johnson shares fell 0.6% to $238.64 in after-hours trading Monday as healthcare stocks lagged, despite gains in the broader market. The company will present at the Barclays Global Healthcare Conference on March 10. J&J faces over 67,500 talc lawsuits, with a New Jersey court last week disqualifying a plaintiffs’ firm. The board declared a $1.30 quarterly dividend, with the stock going ex-dividend Feb. 24.
10 February 2026
·
Johnson & Johnson stock price: JNJ near 52-week high as talc ruling, heart-device data set up Monday

Johnson & Johnson stock price: JNJ near 52-week high as talc ruling, heart-device data set up Monday

A New Jersey appeals court disqualified Beasley Allen from representing plaintiffs in consolidated state talc cases against Johnson & Johnson; the firm plans to appeal. J&J shares closed up 0.93% at $239.99, near a 52-week high, before slipping slightly after hours. The company also reported positive pilot data for its investigational AFib platform.
8 February 2026
··
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
7 February 2026
··
P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

Procter & Gamble shares rose 1.1% to $158.61 in after-hours trading, outperforming broader market declines. CEO Ma. Fatima D. Francisco sold 8,000 shares at $158 each on Feb. 4, according to a regulatory filing. U.S. jobless claims increased to 231,000, while job openings fell to 6.542 million. P&G’s Gillette Venus announced a partnership with U.S. Figure Skating ahead of the Milano Cortina Winter Games.
6 February 2026
···
JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

Johnson & Johnson shares rose 1.3% to $237.59 after the company asked the U.S. Supreme Court to review a shareholder lawsuit over talc safety claims. The petition challenges a Third Circuit ruling on class certification standards. The case is separate from ongoing talc injury suits. Investors are also watching for new data on J&J’s atrial fibrillation devices at a cardiology event this week.
5 February 2026
··
1 2 3 … 8

Stock Market Today

  • Chainlink Powers Blockchain's Real-World Integration Amid Growing DeFi Demand
    April 30, 2026, 9:18 PM EDT. Chainlink provides critical infrastructure enabling blockchains to connect with real-world data and systems. Over 70 major financial institutions and around 70% of decentralized finance (DeFi) applications rely on Chainlink's platform, highlighting its central role in blockchain-based financial services. This integration helps accelerate the adoption of blockchain technology in mainstream finance by ensuring secure, reliable external data access. Chainlink's wide range of software and infrastructure solutions supports the growing DeFi ecosystem and institutional use cases. Bitwise Asset Management, a global crypto asset manager with $11 billion in assets, highlights Chainlink's mission-critical status and investment potential in its recent white paper.

Latest article

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

30 April 2026
Nvidia shares dropped 4.6% to $199.57 Thursday as investors reacted to Alphabet and Amazon expanding sales of their own AI chips. Alphabet reported Google Cloud revenue up 63% and began selling TPU chips directly to customers. AMD and Broadcom shares rose 5.1% and 3.0%, respectively. Amazon said its Trainium chip line secured $225 billion in revenue commitments.
Go toTop